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Non-invasive brain stimulation for 
the treatment of symptoms following 
traumatic brain injury
Simarjot K. Dhaliwal† , Benjamin P. Meek† and Mandana M. Modirrousta *
Department of Psychiatry, University of Manitoba, Winnipeg, MB, Canada
Background: Traumatic brain injury (TBI) is a common cause of physical, psychological, 
and cognitive impairment, but many current treatments for TBI are ineffective or produce 
adverse side effects. Non-invasive methods of brain stimulation could help ameliorate 
some common trauma-induced symptoms.
Objective: This review summarizes instances in which repetitive Transcranial Magnetic 
Stimulation (rTMS) and transcranial Direct Current Stimulation (tDCS) have been used 
to treat symptoms following a TBI. A subsequent discussion attempts to determine the 
value of these methods in light of their potential risks.
Methods: The research databases of PubMed/MEDLINE and PsycINFO were electron-
ically searched using terms relevant to the use of rTMS and tDCS as a tool to decrease 
symptoms in the context of rehabilitation post-TBI.
Results: Eight case-studies and four multi-subject reports using rTMS and six multi- 
subject studies using tDCS were found. Two instances of seizure are discussed.
Conclusion: There is evidence that rTMS can be an effective treatment option for some 
post-TBI symptoms, such as depression, tinnitus, and neglect. Although the safety of 
this method remains uncertain, the use of rTMS in cases of mild TBI without obvious 
structural damage may be justified. Evidence on the effectiveness of tDCS is mixed, 
highlighting the need for additional investigations.
Keywords: traumatic brain injury, non-invasive brain stimulation, repetitive transcranial magnetic stimulation, 
trancranial direct current stimulation, rehabilitation, depression, altered states of consciousness
introduction
Traumatic Brain injury
Traumatic brain injury (TBI) involves the temporary or permanent impairment of brain function 
following physical trauma to the head. TBI commonly occurs as result of falls, motor vehicle acci-
dents, combat trauma, intentional violence, and sports-related incidents (1). TBI is a leading cause 
of death and disability, particularly amongst the young and the elderly (1). The annual incidence 
of TBI in North America is ~2000 out of every 1 million individuals, with an estimated 1.5 million 
Americans experiencing a TBI each year (1, 2).
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Physical damage to brain tissue and blood vessels can occur 
directly as a result of a focal impact to the skull or a rapid accel-
eration of the head. However, brain damage is not limited to the 
moment of initial trauma, as subsequent intracranial events can 
also cause a great deal of problems. These secondary injuries 
can result from both physical and biochemical processes in the 
brain, such as glutamatergic excitotoxicity, a compromised blood 
brain barrier, disrupted blood vessels, and changes in intracranial 
pressure that can lead to contusions, hemorrhages, edemas, or 
hematomas. Furthermore, tissue damage is not always limited 
to the initial point of skull impact. Damage can also occur on 
the opposite side of the brain to the point of impact – contra-
coup – or more diffusely, with frontal and temporal lobes often 
bearing the brunt of such disturbance (1).
Brain injury occurs along a continuum of severity, affecting a 
variety of structures depending on the location of impact. Thus, 
despite many individuals exhibiting ostensibly similar injuries, 
there is a large heterogeneity in the presentation of symptoms (3). 
Impairments following a mild TBI can be affective (depression, 
anxiety, and psychosis), somatic (tinnitus, hypersensitivity to 
noise and light), and/or cognitive (deficits in attention, concen-
tration, information processing, memory, problem solving, and 
thinking) (3–6). Affective symptoms are common following TBI, 
with anywhere from 10 to 77% of patients experiencing the onset 
of depressive symptoms post-injury (6–8). Somatic complaints 
are also frequent, with tinnitus being reported in roughly 50% of 
TBI cases and some individuals experiencing auditory hallucino-
sis (9). Severe TBI involves more extensive trauma, with injuries 
often leading to permanent impairment of brain functions and 
disorders of consciousness, ranging from comatose to minimally 
conscious (10).
The current treatments available for rehabilitation following 
a TBI vary greatly depending on the primary symptoms being 
expressed. Pharmacotherapy is a common treatment for TBI-
induced depression, but reports are mixed as to its effectiveness. 
Furthermore, due to brain vulnerability following a TBI, the 
side effects of psychotropic medications are often accentuated. 
Tricyclic antidepressants, for example, have been reported to have 
adverse effects, including seizures, in patients with TBI (6). In a 
2009 review, Fann and colleagues found no definitive evidence for 
the efficacy of any specific class of medications in the treatment 
of depression in TBI (6). The authors highlight preliminary evi-
dence for SSRIs – particularly sertraline (11, 12) and citalopram 
(13) – and one dual-action SNRI [milnacipran (14)] as potentially 
useful interventions, as well as reports that methylphenidate 
may improve the rate of functional recovery in the post-acute 
phase of TBI (15, 16). However, evidence for the efficacy of these 
interventions is not always consistent (17), and the use of other 
agents, such as bromocriptine, amantadine, donepezil, levodopa/
carbidopa, and dextroamphetamine, are largely limited to case 
reports (18). At present, no medication has received approval 
from the United States Food and Drug Administration (FDA) for 
the treatment of any neuropsychiatric consequence of TBI. Many 
different methods have been employed to reduce the severity 
of TBI-induced tinnitus and auditory hallucinations including 
anti-anxiety medication, acupuncture, osteopathy, hyperbaric 
oxygen therapy, steroids, acoustic stimulation, and behavioral 
intervention with varying degrees of success (19–21). In cases 
of severe TBI, standard rehabilitation attempts to improve func-
tional recovery have generally displayed limited utility (22).
These examples highlight the need for additional therapies to 
be explored for effective management of symptoms following TBI. 
To this end, non-invasive neurostimulatory and neuromodula-
tory tools, such as transcranial Direct Current Stimulation (tDCS) 
and repetitive Transcranial Magnetic Stimulation (rTMS), may 
offer therapeutic alternatives for the treatment of symptoms and 
sequelae following TBI.
Transcranial Magnetic Stimulation
Transcranial magnetic stimulation is a neuromodulatory tool 
used to non-invasively induce neural activity through the use 
of rapidly alternating magnetic fields. A TMS machine contains 
a capacitor that produces a brief electrical current which is run 
through a coil, creating a magnetic field centered at the focal point 
of the coil. The magnetic field is able to pass through the bone of 
the skull and induce activity in cortical neurons below. Pulses can 
be delivered repetitively to produce long-term changes in neural 
activity. Cortical excitability can be either increased or decreased 
through the application of high- (>5  Hz) or low- (1  Hz) fre-
quency stimulation, respectively (23, 24). Repetitive TMS (rTMS) 
therapy has proven to be a safe and effective option for alleviating 
symptoms of treatment-resistant depression (25–27).
One of the major advantages of rTMS is its relative safety and 
the absence of major adverse side effects when established guide-
lines are followed. The most common side effects of rTMS include 
headache and minor scalp irritation following therapy, but these 
effects tend to be transient and easily treated with common 
analgesics (23). More distressing side effects, such as confusion 
and memory loss, which are commonly associated with electro-
convulsive therapy, have not been reported following rTMS. The 
major concern with rTMS is the risk of seizure-induction (24). 
Although the incidence of seizure following rTMS in normal 
populations is low, it is of greater concern when rTMS is being 
considered for individuals who demonstrate an increased likeli-
hood of seizure. For this reason, conditions that accompany an 
increased likelihood of seizure, such as TBI, pro-epileptogenic 
medication, substance abuse, or a family history of epilepsy, are 
commonly considered contraindications for treatment (23).
Despite the potential risks, past reviews have suggested that 
insights gained from the therapeutic use of rTMS in patients 
with non-trauma-induced brain injuries (e.g., stroke, Parkinson’s 
disease, or spinal cord injury) may be applicable to patients with 
TBI (22, 28). For example, inhibition of the unaffected hemisphere 
through the use of low-frequency (1  Hz) rTMS has produced 
improvements in hand motor dysfunction and aphasic symptoms 
following stroke (29, 30). Transient inhibition of the contralesional 
parietal region via low-frequency rTMS has been shown to improve 
line bisection and clock drawing task performance in patients with 
visuospatial neglect (31). High-frequency (5 Hz) rTMS applied to 
the primary motor cortex in the hemisphere contralateral to pain 
has reduced neuropathic pain and improved clinical spasticity in 
patients with non-trauma induced brain damage (32–34). The use 
of rTMS in healthy populations following the induction of virtual 
lesions also offers insights into the use of rTMS in patients with real 
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brain damage. For example, healthy patients demonstrate riskier 
decision making when virtual lesions in the right dorsolateral 
prefrontal cortex (DLPFC) are induced via TMS (35). Based on 
this observation, Demirtas-Tatlidede et al. suggest that impaired 
decision making following a TBI may be improved by increasing 
right DLPFC activity via high-frequency rTMS (22).
Despite the demonstrated utility of single-pulse TMS in the 
diagnosis of TBI and the potential usefulness of rTMS in treating 
common TBI symptoms, brain injury is usually considered a con-
traindication to the repetitive form of TMS due to increased overall 
neural excitability and seizure risk. For this reason, TBI patients 
are excluded from most rTMS studies making it difficult to readily 
assess the efficacy and safety of rTMS as a treatment for TBI (23).
Transcranial Direct Current Stimulation
Transcranial direct current stimulation is a non-invasive neuro-
modulatory tool which uses low amplitude direct current to alter 
neuronal firing (22). Transcranial applications of direct current 
can induce focal, prolonged shifts of cortical excitability using 
anodal or cathodal stimulation to increase or decrease cortical 
excitability, respectively (36, 37). Clinically significant improve-
ments have been seen in patients with brain damage due to stroke, 
with behavioral effects persisting for weeks following tDCS treat-
ment (38, 39). The administration of tDCS has also been found to 
be safe and effective in the treatment of major depressive disorder 
(40–42). Adverse effects of tDCS treatment include moderate 
fatigue (35%), mild headache (11.8%), nausea (2.9%), and a tran-
sient itching sensation in area of stimulation (43, 44). According 
to Nitsche et al., no cases of seizure have been reported in relation 
to the use of tDCS as a clinical intervention (45).
With the demonstrated effectiveness of tDCS applications in 
the treatment of depression (46), Demirtas-Tatlidede et al. pro-
pose that these applications could find utility for treating patients 
with traumatic brain injuries (22). The authors theorize that bilat-
eral tDCS to the left and right DLPFC could result in clinically 
significant reduction of depressive symptoms with onset follow-
ing TBI. Such suggestions extend insights made in patients with 
brain damage due to stroke and suggest that left frontotemporal 
cathodal tDCS could improve naming in patents with non-fluent 
aphasia due to TBI (47). Other potential applications of tDCS 
in cases of TBI include bilateral tDCS to the DLPFC to improve 
decision-making impairments and modulation of sensorimotor 
cortical activity to suppress central pain (22, 48).
In this systematic review, we present studies that have used 
rTMS or tDCS in the treatment of symptoms following a TBI to 
examine the safety and efficacy of indirect cortical stimulation 
in this patient population, and we consider the potential impact 
these results may have on established safety guidelines. Due to 
the diverse and debilitating nature of traumatic brain injuries 
and the limited efficacy of available clinical options, these novel 
treatments are worth exploring.
Methods
The research databases of PubMed/MEDLINE and PsycINFO 
were electronically searched using the terms “transcranial 
magnetic stimulation”, “transcranial direct current stimulation”, 
“brain injuries”, “concussion”, and “consciousness disorders”. 
The MeSH approach was utilized to restrict PubMed findings to 
transcranial magnetic stimulation (TMS) and transcranial direct 
current stimulation (tDCS) as a tool to decrease symptoms, and 
to restrict TBI in the context of therapy and rehabilitation. The 
references of articles found through our search method were 
also reviewed. Articles were selected manually and limited to 
English articles from the last 10  years with focus on repetitive 
TMS (rTMS) and tDCS as tools to decrease symptoms for TBI 
and rehabilitation post-TBI. A PRISMA flow diagram outlining 
the search methodology is shown in Figure 1.
Results
We found 10 articles and 1 abstract that involve the use of rTMS 
as a therapeutic or rehabilitative tool for symptoms and sequelae 
following TBI. Three articles involve multiple patients, while the 
remaining eight manuscripts present single-case reports  –  two 
of which describe rTMS-related seizure events. The abstract 
discusses 11 individuals, only 2 of whom suffered a TBI. These 
reports address a variety of symptoms, including depression, 
auditory dysfunction, post-concussion symptoms, hemispatial 
neglect, and altered states of consciousness. Relevant details 
from the reviewed rTMS papers are summarized in Table 1. All 
rTMS studies used figure-eight focal coils to administer pulses 
FiGURe 1 | PRiSMA flow diagram outlining search methodology.
TABLe 1 | Summarized details of reviewed rTMS articles.
Study Patient descriptions Brain damage Target 
symptoms
Stimulation 
location
Stimulation 
parameters
# Sessions Outcome
Bonni et al. 
(49)
20 y.o. male; severe TBI 2 years 
prior
Cortical lesion in right temporal cortex; 
small cortico–subcortical lesions in 
periventricular white matter
Hemispatial 
neglect
Left posterior 
parietal cortex
50 Hz cTBS at 80% 
active MT
20 (2/day) Marked cognitive improvement in BIT
Cavinato et al. 
(50)
31 y.o. male; severe TBI 
8 months prior
Diffuse hematoma in corpus callosum; 
mass effect over fourth ventricle
Altered 
consciousness
Left DLPFC 20 Hz at 90% MT 4 prior to 
seizure
Seizure
Cosentino 
et al. (20)
63 y.o. male; TBI of unspecified 
severity 10 months prior
Structural lesion of right temporal lobe Musical 
hallucination
Right temporal 
area
1 Hz at 90% MT using a 
focal coil
10 Disappearance following Tx, reappearance 
in reduced state 4 months post-Tx
Fitzgerald 
et al. (51)
41 y.o. female; mild TBI 14 years 
prior
None Depression DLPFC Active sequential 
stimulation at 110% MT: 
low: 1 Hz; high: 10 Hz
20 Response (50% MADRS reduction)
George et al. 
(52)
n = 41 [n = 21 with mTBI (11 
sham, 13 active rTMS)]
Not specified Suicidal ideation Left prefrontal 
cortex
10 Hz at 110% MT 9 (3/
day × 3 days)
Drop in SSI scores not significantly different 
between groups; trend toward more rapid 
response in active group
Giovannelli 
et al. (53)
n = 2; Both patients in VS 
following severe TBI; ages and 
time since injury not reported
Not specified Altered 
consciousness
Left primary 
motor cortex
20 Hz at 60% max 
output vs sham
5 No significant difference
Koski et al. 
(54)
n = 15 [female = 6; age = 34.3 
(10.8) years; PCS score = 37.5 
(10.9)]
Not specified Post-
concussion 
symptoms
Left DLPFC 10 Hz at 110% MT 20 n = 9: improvement of symptoms (≥5 
reduction on PCS scale); n = 1: worsening 
of symptoms
n(completers) = 12
Kreuzer et al. 
(19)
53 y.o. male; severe TBI 5 years 
prior
Frontotemporal epi- and subdural 
hematoma
Tinnitus Left primary 
auditory cortex
1 Hz at 110% resting MT 10 (repeated 
5 times in 
3 years)
Marked reduction in tinnitus symptoms
Manganotti 
et al. (55)
n = 3 Patient 1: subdural hematoma; diffuse 
cortical lesions
Altered 
consciousness
Left/right primary 
motor cortex
20 Hz at 100% MT 1 Patient 1: no EEG change, slight increase 
visual JFK CRS-R
Patient 1: 37 y.o. female in VS 
34 months post-TBI
Patient 2: multifocal bifrontal lesions Patient 2: no EEG change, slight increase 
visual JFK CRS-R
Patient 2: 29 y.o. male with MCS 
94 months post-TBI
Patient 3: pontomesencephalic lesion Patient 3: no difference
Patient 3: 38 y.o. male with MCS 
36 months post-TBI
Pachalska 
et al. (56)
20 y.o. male; severe TBI 
3–4 years prior
Diffuse atrophy and enlarged 
ventricles in the RH
Impaired 
executive 
functioning
Right + left 
frontal/temporal 
regions
1 Hz to LH and 5 Hz 
to RH
20 Large improvements in most tests of 
executive functioning and all categories of 
the FBI
Louise-Bender 
Pape (10)
26 y.o. male in VS 287 days 
post-TBI
Hemorrhage in lateral and fourth 
ventricles and right temporal lobe; 
diffuse subarachnoid hemorrhage
Altered 
consciousness
Right DLPFC Paired 100 μs pulse 
trains with 100 ms ISI 
and 5 s ITI at 110% MT
30 Increased DOCS; clinical, behavioral 
improvement
Louise-Bender 
Pape (57)
32 y.o. male in VS 9 years 
post-TBI
Multicystic encephalomalacia of RH 
and basal ganglia; hypoattenuation in 
the anterior frontal lobe; dilatation of 
3rd and lateral ventricles
Altered 
consciousness
Left DLPFC Paired 100 μs pulse 
trains with 100 ms ISI 
and 5 s ITI at 110% MT
21 prior to 
seizure; 19 
post-seizure
Electrographic seizure; improvement 
in following one-step commands and 
purposeful vocalizations prior to seizure
y.o., years old; TBI, traumatic brain injury; Tx, treatment; cTBS, continuous theta burst stimulation; rTMS, repetitive transcranial magnetic stimulation; tDCS, transcranial direct currant stimulation; DLPFC, dorsolateral prefrontal cortex; 
MT, motor threshold; BIT, Behavioral Inattention Test; MADRS, Montgomery–Åsberg Depression Rating Scale; SSI, Beck Scale of Suicidal Ideation; PCS, post-concussion syndrome; EEG, electroencephalogram; JFK CRS-C, JFK 
Coma Recovery Scale-Revised; FBI, frontal behavioral inventory; DOCS, Disorders of Consciousness Scale; RH, right hemisphere; LH, left hemisphere.
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unless otherwise noted. We found six articles that describe the 
use of tDCS in multiple individuals with TBI. Three articles focus 
on the restoration of cognitive symptoms – primarily attention 
and memory, two describe attempts to improve altered states of 
consciousness, and one used tDCS in conjunction with physi-
cal therapy to ameliorate upper extremity motor dysfunction. 
Relevant details from the reviewed tDCS papers are summarized 
in Table 2. Owing to the heterogeneity of TBI cases, an in-depth 
examination of the protocols used and any concurrent conditions 
and/or medications are presented.
rTMS
Treatment of Post-Injury Onset of Depression and 
Suicidal Ideation
Fitzgerald et al. report rTMS treatment for a pharmacotherapy-
resistant 41-year-old female patient with severe recurrent 
depression [Montgomery–Åsberg Depression Rating Scale 
(MADRS) = 34; Inventory of Depressive Symptomology-Clinical 
Rated (IDS-CR) = 49] persisting for 14 years with onset following 
a mild closed-head TBI and no prior history of brain injury (51). 
Magnetic resonance imaging (MRI) and diffusion tensor imaging 
(DTI) demonstrated no contraindication to rTMS and no presence 
of diffuse axonal injuries. Desvenlafaxine was held at a constant 
dosage 8  weeks prior to treatment and throughout the course 
of rTMS. Active sequential bilateral rTMS was administered to 
the DLPFC (right-sided low-frequency rTMS followed by left-
sided high-frequency rTMS). A single stimulation train (1 Hz, 
900 pulses/session) administered at 110% of resting MT during 
right-sided low-frequency rTMS was immediately followed by 30 
trains (10 Hz, 5 s train duration, 25 s inter-train interval), at 110% 
of resting MT for left-sided high-frequency rTMS. The patient 
showed a positive response to treatment with a greater than 50% 
reduction in depressive symptoms (MADRS = 14; IDS-CR = 21). 
Neuropsychological assessments of attention, concentration, 
working memory, speed of information processing, verbal and 
visual memory, perceptual ability, and executive functioning 
showed no deleterious changes in cognitive performance. No 
adverse side effects of treatment were reported.
George et al. administered high-frequency rTMS (10 Hz, 5 s 
train duration, 10 s IT for 30 min) at 110% resting MT over the 
left prefrontal cortex to suicidal inpatients (Beck Scale of Suicidal 
Ideation score ≥12 and ≥3 on Question #3 of the Ham-D) in a 
randomized, sham-controlled study (52). Each session delivered 
6000 pulses over 30 min, and sessions were repeated three times 
daily with 1 h between sessions for 3 days (total 9 sessions and 
54,000 pulses). 41 patients with a diagnosis of either PTSD or 
mTBI were recruited for this study (20 active and 21 sham). Of 
these patients, 21 individuals had previously suffered a TBI (13 
active and 11 sham). The protocol was generally well tolerated 
with no major side effects, although one patient suffered a first-
degree scalp burn from coil overheating. The authors report a 
trend toward a more rapid change in SSI in the active rTMS group 
compared to the sham group, but there was no overall difference 
in the change in SSI between groups. Patients showed a reduc-
tion in how much they were bothered by thoughts of suicide, 
but they demonstrated no difference in future intent of suicide, 
thoughts of suicide, self-rated sadness, tiredness, or happiness. 
The authors note that patients continued to receive standard 
inpatient care –  including changes in medication – throughout 
the study, so the observed results cannot be separated from any 
non-specific hospitalization effect. Results were not broken down 
between patients with PTSD and TBI, so conclusions cannot be 
drawn regarding the efficacy of this protocol specifically in rela-
tion to TBI. However, the fact that this rather aggressive protocol 
was generally well tolerated demonstrates its feasibility.
Treatment of Post-Injury Onset of Auditory 
Dysfunction
Kreuzer et al. report rTMS treatment of severe tinnitus [tinnitus 
questionnaire (TQ) = 53] persisting for 4 years following a severe 
TBI in a complex 53-year-old male patient. The patient presented 
with co-morbid post-injury onset depression and associated 
severe sleep disorder, alcohol and benzodiazepine abuse, as well 
as a single symptomatic seizure immediately following injury 
with no subsequent seizures (19). Tinnitus symptoms displayed 
resistance to prior treatments of acupuncture, osteopathy, 
hyperbaric oxygen therapy, intravenous application of steroids, 
and acoustic stimulation. Treatment began once alcohol and ben-
zodiazepine intake were excluded via laboratory screening tests 
administered through the course of rTMS, with antidepressant 
(75 mg amitriptyline) and antiepileptic (150–300 mg pregabalin) 
dosage kept constant throughout treatment. Trains of stimula-
tion at 110% resting MT (1 Hz, 2000 stimuli/session) applied to 
the left primary auditory cortex for 10 sessions demonstrated 
a positive effect lasting 3 months after the first treatment series 
(TQ = 38). Four subsequent treatment series over the course of 
3 years demonstrated effects lasting 6 months (TQ = 26 after third 
session, no ratings taken after fourth session). The fifth and final 
series followed a modified protocol targeted at the right DLPFC 
(1  Hz, 1000  pulses/session) followed by stimulation applied to 
the left primary auditory cortex (1 Hz, 1000 pulses/session) for a 
duration of 5 days (beginning of fifth session TQ = 50; following 
treatment TQ = 33). The authors state that the patient remained 
abstinent from alcohol and benzodiazepines throughout treat-
ment. The patient reported a reduction in loudness of tinnitus, 
and treatment was reported to be well tolerated without adverse 
effects or seizures as a result of rTMS intervention.
Cosentino et al. report the use of rTMS in the treatment of 
musical hallucinosis (a form of auditory hallucination) with an 
onset of 10 months following right temporal injury in a 63-year-
old male patient with prior moderate–severe hearing loss (hear-
ing loss remained constant throughout and following treatment) 
from chronic daily noise exposure over 20 years (20). EEG scans 
showed an absence of epileptiform abnormalities. PET scans 
demonstrated hypoactivity in the corresponding temporal lesion 
and increased metabolic activity in the right posterior temporal 
lobe. MRI revealed a contusion of the right temporal pole, but 
neurological and neuropsychological status was normal for age 
and education level as assessed by memory, attention, language, 
apraxia, and visuospatial tests. Treatment with antiepileptics 
(gabapentin and carbamazepine) and antipsychotics (risperidone 
and paroxetine) was unsuccessful in the months prior to rTMS. 
Stimulation was applied to the right posterior temporal cortex at 
90% MT (1 Hz, 1200 pulses/session; 20 min train duration) for 
TABLe 2 | Summarized details of reviewed tDCS articles.
Study Patient descriptions Brain damage Target 
symptoms
Stimulation location Stimulation parameters # Sessions Outcome
Angelakis 
et al. (58)
n = 4; 3 in PVS, 1 in MCS− 
following severe closed-
head TBI; age range 19–37; 
6 months–10 years post-TBI
Not specified Altered 
consciousness
Anode: left DLPFC or 
left primary sensorimotor 
cortex
Week 1: 
1 mA/25 cm2 × 20 min
10 Patient 1: PVS to MCS− 1 yr post-tDCS; 
Patients 2 and 3: no improvement; Patient 
4: MCS− to MCS+ 1 week post-tDCS and 
conscious 2 weeks post-tDCSCathode: right orbit Week 2: 
2 mA/25 cm2 × 20 min
Kang et al. 
(59)
n = 9, 5 sham; 8 males; age 
range 20–78; 216.9 (52.5) days 
post-closed head TBI
Various (all: SDH or ICH to 
left or bilateral frontal lobes; 
n = 4: additional parietal, 
temporal, occipital, or 
cingulate damage)
Attention 
deficits
Anode: left DLPFC 2 mA/25 cm2 × 20 min 1 Immediate but not lasting improvement in 
attentionCathode: contralateral 
supraorbital region
Les´niak 
et al. (60)
n = 23, 11 sham; age range 
20–45 years; 4–92 months 
post-TBI
Various (incl. frontal/parietal/
temporal/occipital contusion; 
cerebellum or BS damage)
Memory and 
attention 
deficits
Anode: left DLPFC 1 mA/35 cm−2 × 10 min 15 No improvements in attention or memory
Cathode: contralateral 
supraorbital region
Middleton 
et al. (61)
n = 5 [1 TBI (age 39, time 
since injury = 206 months), 1 
TBI + stroke (age = 38; 9 months 
post-injury)]
Not specified; both TBI 
patients had motor issues 
affecting their left UE
Motor 
impairments
Anode: ipsilesional motor 
cortex
1.5 mA/25 cm2 × 15 min 24 Improvement on UE-FM – persisted at a 
6-month follow-up
Cathode: contralesional 
motor cortex
Thibaut 
et al. (62)
n = 25, 6 post-traumatic UWS; 
n = 30,19 post-traumatic MCS
Not specified Altered 
consciousness
Anode: left DLPFC 2 mA/35 cm2 × 20 min 1 UWS patients: no improvement; MCS 
patients: improved consciousness
Cathode: contralateral 
supraorbital region
Ulam et al. 
(63)
n = 23; 13 treatment [age 31.4 
(9.8); 57.4 (37.8) days post-
injury], 13 sham [age 35.7 (13.7); 
41.1 (20.9) days post-injury]
Various (incl. SDH, SAH, 
frontal/parietal/temporal/
occipital contusion; three 
severe TBI) 
Various 
neuropsych. 
functions 
(including 
attention and 
memory)
Anode: left DLPFC 1 mA/25 cm2 × 20 min 10 No difference in neuropsych. improvement 
between groups Active group only: 
correlation between cortical excitability and 
neuropsych. improvement
Cathode: contralateral 
supraorbital region
PVS, persistent vegetative state; MCS, minimally conscious state; DLPFC, dorsolateral prefrontal cortex; SDH, subdural hemorrhage; ICH, intracerebral hemorrhage; SAH, subarachnoid hemorrhage; BS, brain stem; UE, upper 
extremity; UWS, unresponsive wakefulness syndrome; UE-FM, Fugl-Meyer Assessment of Sensorimotor Impairment – upper extremity section.
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2 weeks. The severity of musical hallucinations decreased from 
5 to 8 points prior to treatment to 2 points post-treatment on a 
10-point scale created to measure symptom severity. PET scans 
during 5 months of follow-up sessions demonstrated decreased 
hyperactivity of right posterior temporal cortex and decreased 
metabolic activity of the right posterior temporal lobe but persist-
ing hypoactivity of the temporal lesion. Cognitive abilities were 
not tested following rTMS intervention. No adverse effects were 
reported.
Rehabilitative Applications for Post-Injury Cognitive 
Impairments
Theta burst stimulation (short trains of rTMS at high frequen-
cies) applied to the left hemisphere has been seen to improve the 
symptoms of hemispatial neglect in patients with brain injury 
due to stroke (64). Bonni et al. extended these insights for use 
in a patient with brain injury due to trauma (49). The authors 
used continuous theta burst stimulation (cTBS) to treat severe 
hemispatial neglect in a 20-year-old male patient with onset fol-
lowing a severe TBI [Behavioral Inattention Test-Conventional 
(BIT-C) scale ~28] sustained 2  years prior to intervention. 
Neuropsychological assessments demonstrated mild attentional 
and executive deficits and minimal memory impairment. Three 
pulse bursts were applied to the left posterior parietal cortex at 
80% active MT (50  Hz, 600  pulses/session; 40  s train interval, 
200  ms inter-train interval) twice daily (15  min inter-session 
interval) for 2  weeks. Functional magnetic resonance images 
(fMRI) demonstrated decreased excitability of posterior parietal 
cortex-M1 connections in the left hemisphere and a bilateral 
increase of functional connectivity in the frontal-parietal net-
work. In conjunction with these functional changes, marked 
cognitive and clinical improvements were reported and seen to 
persist 2 weeks following intervention (BIT-C ~ 58). No adverse 
effects were reported.
Pachalska et al. administered rTMS to a 26-year-old male who 
had previously (3–5 years) suffered a severe TBI which left him 
in a coma for 2 months (56). Brain scans revealed diffuse atrophy 
and enlarged ventricles in the right hemisphere, and the patient 
exhibited anosognosia, executive dysfunction, behavioral changes; 
perseverations, fits of uncontrolled laughter, and was sporadically 
aggressive and impulsive. Twenty sessions of low-frequency 
(1 Hz) rTMS were administered over left frontal and temporal 
regions along with high-frequency (5 Hz) rTMS to right frontal 
and temporal regions. Following rTMS, the patient showed large 
improvements in most tests of executive functioning, including: 
general intelligence, attention, visuospatial ability, and logical 
memory. He also showed improvement on all categories of the 
frontal behavioral inventory, including: social conduct, personal 
conduct, mood disorders, and control disorders. The authors state 
that the patient had previously shown little progress following 
“traditional rehabilitation” and only small changes following beta 
training. Although EEG spectra were no different post-rTMS, 
NO-GO ERP recordings showed improvement compared to 
pre-rTMS, though still much different from healthy controls. No 
seizure events or significant adverse side effects were reported.
Recently, Koski et al. examined the effect of high-frequency 
rTMS on individuals experiencing post-concussion syndrome 
(PCS) at least 6 months post-injury (54). 15 patients with a score 
of 22 or greater on the PCS Scale received 20 daily sessions of 
rTMS (10 Hz at 110% resting MT; 20 5  s trains with 25  s ITI; 
1000 pulses/session) over the left DLPFC. Two patients quit due 
to worsening symptoms and one for unrelated reasons. Of the 
12 patients who completed treatment, 9 showed an improvement 
in symptoms (>5 point decrease on PCS scale) and 1 patient 
worsened. Patients also showed an overall decrease in ratings 
of headaches, as well as a (statistically uncorrected) decrease in 
symptoms of fatigue, trouble falling asleep, difficulty remember-
ing, and numbness or tingling. No seizure events or serious side 
effects were reported. Nine out of twelve patients found 110% MT 
stimulation to be intolerable in the first session, but all patients 
tolerated this intensity by the sixth session following gradual 
intensity increases. fMRI scans demonstrated greater activations 
in DLPFC and greater deactivation of the rostral ACC during 
a working memory task following the last session compared to 
pre-treatment. Results of a 3-month follow-up with some patients 
indicate that maintenance treatments may be required to sustain 
the observed gains.
Rehabilitative Applications for Post-Injury Loss of 
Consciousness
Louise-Bender Pape et  al. examined the safety and restorative 
effects of rTMS by attempting to restore consciousness following 
a severe TBI (10). They used rTMS to induce neurobehavioral 
changes in a 26-year-old male who remained in a vegetative 
state 287  days after a severe TBI. Computerized tomography 
(CT) scans revealed hemorrhage in the right temporal lobe as 
well as diffuse traumatic subarachnoid hemorrhage. The patient 
was described to be in a state of arousal without behavioral 
evidence of awareness of self or capacity to interact with the 
environment [Disorders of Consciousness Scale (DOCS) = 50.3]. 
Prior to treatment, the patient was titrated off neurostimulants 
(amantadine and methylphenidate) and antispasticity medica-
tions and did not receive any neurological medication during the 
course of the intervention. Safety was ensured by administering a 
modified lower-than-normal frequency rTMS protocol following 
completion of a daily medical examination, with an electroen-
cephalogram (EEG) conducted before and after each session and 
continued bi-weekly for 6 weeks post-treatment. Stimulation was 
administered to the right DLPFC at 110% abductor pollicis brevis 
MT (300 trains/session with a 5 s inter-train interval, where each 
train consisted of a paired-pulse with a 100 ms inter-pulse inter-
val) for 6 weeks. The patient experienced complications that the 
authors concluded were not related to the rTMS intervention. The 
patient was treated with 2 g Ceftazidime, 1 g vancomycin, 900 mg 
amikacin, and 500 mg Cipro. No adverse effects were reported as 
a result of rTMS treatment, and EEGs performed throughout and 
following the treatment revealed lack of epileptiform discharges 
following rTMS. The authors report a change in classification 
of state of consciousness from vegetative state to minimally 
conscious (DOCS: 15th session = 58.6; 30th = 53.7; 6 weeks post-
treatment = 56.7). Qualitative improvements through the course 
of rTMS were reported, including markedly improved motor 
skills and visual ability, the appearance of vocalizations, and the 
development of basic communication. Continued qualitative 
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improvements were reported a year following rTMS treatment 
by the patient’s family, with no reported adverse events.
Manganotti and colleagues administered high-frequency 
rTMS to three patients with severe brain injuries due to TBI. Two 
patients were classified as minimally conscious, while the third 
was in a vegetative state (55). Safety criteria included absence of 
contraindication to rTMS, stability of vital parameters, and more 
than 12 months since injury. A single session was administered 
to the primary motor cortex at 100% MT (20 Hz, 1000 pulses/
session; 5 s train duration, 20 s inter-train interval) for 10 trains. 
A clinical response was not witnessed in any of the three patients, 
with EEG demonstrating no reaction to brain stimulation and 
a decrease in MT. No adverse effects or seizures were reported.
Similarly, Giovannelli and colleagues reported no clinically 
significant neurobehavioral change following rTMS therapy for 
two patients in a vegetative state due to TBI (53). Using a rand-
omized, double-blind cross-over design with a sham stimulation 
control, high-frequency rTMS was applied to the left M1 at 60% 
stimulator output (20 Hz or sham; 1000 pulses/session) for five 
consecutive days. The patients did not demonstrate statistically 
significant improvement compared to sham stimulation as meas-
ured using the JFK Coma Recovery Scale-Revised (CRS-R) and 
Clinical Global Impression (CGI) rating.
Seizure Events in Patients with TBI Following rTMS 
Intervention
Cavinato et al. report the occurrence of a partial and secondarily 
generalized tonic–clonic seizure in a 31-year-old male patient 
who suffered a severe TBI 8 months prior to rTMS intervention 
(50). MRIs following the TBI revealed diffuse hematoma in 
corpus callosum with mass effect over the fourth ventricle and 
upstream hydrocephalus. Prior to treatment, the patient received 
medication for gastric disorder and spasticity (2 ml Diazepam), 
and he had no prior personal or family history of epilepsy or 
seizure disorder. Treatment began once stable clinical conditions 
were demonstrated and baseline EEG excluded epileptiform and 
paroxysmal activity. Three of ten daily sessions at 90% abductor 
pollicis brevis MT (20 Hz, 1 s train duration, 1 min inter-train 
interval) applied to the DLPFC were tolerated without adverse 
effects. Three hours after the fourth rTMS session, the patient 
experienced an adversive seizure followed by a secondary gen-
eralized seizure and a complete loss of consciousness, with no 
urinary or bladder incontinence or tongue beating. EEG reports 
following the seizure showed slowing with focal spike discharges 
in the left fronto-central areas. Reports taken 2  days following 
the seizure displayed no epileptiform activity and demonstrated 
a return to baseline levels, with no antiepileptic medication 
administered at any time.
Louise-Bender Pape et  al. report an electrographic seizure 
with no clinical accompaniment in a patient in a vegetative state 
following 21 sessions of rTMS (57). The patient was a 32-year-old 
male who had suffered a TBI 9 years prior and had a GCS score 
of 6 at injury. Head CT prior to treatment revealed “multicystic 
encephalomalacia of almost the entire right cerebral hemisphere 
and most of the basal ganglia as well as hypoattenuation in the 
anterior frontal lobe and dilatation of third and lateral ventricles.” 
Stimulation was applied using a paired-pulse technique with two 
100 μs pulses applied at an interval of 100 ms, followed by 5 s of 
rest. Daily sessions of 300 pulses at 110% MT were administered 
over the left DLPFC. Neural activity was monitored using daily 
EEG recordings pre- and post-rTMS. Prior to the seizure, EEGs 
showed no evidence of epileptiform discharges or periodic com-
plexes, but the authors note the presence of some neurophysi-
ological disturbances indicated by slow wave abnormalities in the 
right central–parietal, right temporal, and left temporal areas. The 
electrographic activity originated in the right central–parietal 
region and extended to the mid-central and right temporal areas. 
The event lasted longer than 90 s, but stopped without medica-
tion. Subsequent EEGs were no different from recordings taken 
prior to the seizure. The patient was placed on 1000 mg leveti-
racetam and monitored carefully for a week. rTMS treatments 
were then resumed at 2% lower stimulation intensity and with 
100 fewer pulses per  session for an additional 19 sessions. No 
further adverse events were reported. The authors note that this 
rTMS-triggered seizure is unusual as it originated contralateral 
to site of stimulation.
tDCS
Therapeutic Applications for Post-Injury Cognitive 
Impairments
In a double-blind cross-over study (N = 9), Kang et al. reported 
immediate but not lasting improvement in the attention of 
patients with TBI following a single tDCS session (59). MRI and 
anatomical CT scans demonstrated no significant brain atrophy 
or implants prior to intervention. Patients with a history of seizure 
or co-morbid medical/neurological conditions were excluded, 
and medication was kept constant throughout treatment. A single 
session of tDCS was administered with the anode over the left 
DLPFC (2 mA/25 cm2 × 20 min; sham 1 min on/19 min off) and 
the cathode over the contralateral supraorbital region. Attention 
was measured using a mini-mental status exam (MMSE) and 
computerized contrast reaction time task (CCRTT). The treat-
ment group demonstrated improved attention from baseline 
compared to sham at 1-h follow-up but no significant differences 
were observed at 3 and 24 h post-treatment.
In a randomized double-blind controlled pilot study, Leśniak 
et al. found that repeated applications of tDCS in addition to daily 
rehabilitative cognitive training did not enhance attention or 
memory in patients with severe TBI (60). The study consisted of 
patients (N = 23) aged 18–45 who had experienced a TBI a mini-
mum of 4 months prior to the study accompanied by loss of con-
sciousness and/or post-traumatic amnesia, and no prior history of 
neurological/psychiatric conditions, post-injury seizures, or skull 
fractures/implants in the area of stimulation. Sham and treatment 
groups were randomized and matched by age, time since TBI, and 
severity of symptoms. Fifteen sessions of tDCS with the anode 
over the left DLPFC (1 mA/35 cm2 × 10 min, decreased intensity 
at start and finish; sham 25 s on/9.75 min off) and the cathode 
over the right supraorbital area were administered. Treatment 
was reported to be well tolerated with minor side effects. Fifteen 
computerized cognitive training sessions to improve memory 
were administered following tDCS intervention. Large effect sizes 
for treatment and sham group were reported but no statistically 
significant difference between the two groups was found.
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Ulam et al. used a randomized, double-blind design to test the 
effect of repeated sessions of anodal tDCS on EEG oscillations and 
neuropsychological tests (attention, working memory, inhibitory 
control, cognitive flexibility, immediate and delayed memory for 
verbal and visual-spatial material, and emotion recognition) in 
patients with TBI (63). 23 patients (13 active tDCS and 13 sham) 
received anodal tDCS to the left PFC (1 mA/25 cm2 × 20 min) 
with the cathode over the right supraorbital area. EEG immedi-
ately after one session of tDCS demonstrated increased cortical 
excitability at the location of the anode. This increased excitability 
continued to be present 1  day following the 10th session, but 
was no longer restricted to the anodal location. There was no 
significant difference between the active and sham groups in their 
performance change on the neuropsychological tests, though 
both groups showed an overall improvement. However, there was 
a significant correlation between change in cortical excitability 
and neuropsychological improvement in the active group but 
not the sham group. Additionally, individuals in the active group 
who showed a greater slowing in EEG prior to tDCS intervention 
improved on a greater number of neuropsychological tests than 
did the rest of the active tDCS group.
Rehabilitative Applications for Post-Injury Motor 
Impairments
Middleton et al. report the use of tDCS in conjunction with upper 
extremity physical therapy for patients with motor impairments 
resulting for stroke and/or TBI (N = 5, one with TBI, one with 
TBI + stroke) (61). Bihemispheric tDCS was delivered with the 
anode over the ipsilesional motor cortex (1.5 mA/25 cm2 × 15 min) 
and cathode over the contralesional motor cortex, three times a 
week for 24 sessions, during strengthening and functional activi-
ties. Both TBI patients showed improvement on the Fugl-Meyer 
Assessment of Sensorimotor Impairment UE section (UE-FM), 
which assesses reflexes, range of motion, pain, light touch sensa-
tion, proprioception, movements in and out of synergy, grasp, 
and coordination. This improvement persisted at a 6-month 
follow-up. Performance changes in robotic reach and object-
hit tasks were less consistent. No adverse effects of tDCS were 
reported. This small proof-of-concept study showed that tDCS 
was well tolerated by patients and can be incorporated into physi-
cal training without being a hindrance.
Rehabilitative Applications for Post-Injury Loss of 
Consciousness
Angelakis et  al. report an attempt to restore consciousness 
through the use of tDCS in patients with persistent unrespon-
sive wakefulness syndrome (UWS) following a severe TBI 
(58). Five daily sessions of tDCS were administered with the 
anode over the left DLPFC or left primary sensorimotor cortex 
(1 mA/35 cm2 × 20 min) and the cathode over the right orbital 
region to participants (N =  10, four with TBI, open head TBI 
excluded) with varying degrees of consciousness (assessed by 
JFK Coma Recovery Scale-Revised, JFK CRS-R; monitored by 
EEG and fMRI/FDG-PET). A 22-year-old male patient with 
TBI sustained 6 months prior to treatment (baseline CRS-R: 9) 
showed immediate improvement after a week of (CRS-R: 17) and 
continued improvement after second participation 3 months later 
(CRS-R: 19). A 19-year-old female patient with a TBI sustained 
6 years prior (baseline CRS-R: 8) to intervention demonstrated no 
immediate response to tDCS but improved at a 1-year follow-up 
(CSR-R: 9). Two patients (CRS-R: 6 and 9, respectively) did not 
show any immediate effects (no change in CRS-R) or changes at a 
1-year follow-up. Both patients were males (aged 35 and 37) with 
severe TBIs sustained 7 and 10  years prior, respectively. Based 
on the response of all patients in the study (not just those with 
TBI), the authors observed that the efficacy of tDCS interven-
tion seemed to be dependent on the severity of the disordered 
conscious, with MCS patients responding better than UWS, and 
the time since injury, with more recent injuries faring better.
Thibaut et al. performed a sham-controlled randomized dou-
ble-blind study to determine the effect of tDCS on consciousness 
in patients with UWS (N = 25; 6 post-traumatic) and patients in a 
minimally conscious state (MCS; N = 30; 19 post-traumatic) (62). 
The study employed a cross-over design in which each patient 
received one session of both sham and real tDCS in a randomized 
order. The anodal electrode was placed over the left dlPFC with 
the cathodal (reference) electrode over the right suborbital region 
(2 mA/35 cm2 × 20 min). A subset of patients showed a transient 
improvement in CRS-R score following a single session of tDCS. 
A group effect was seen for the MCS but not for the UWS patient 
group. Although the authors did not assess the effect of treatment 
specifically for post-traumatic patients, their presented data show 
that treatment had no significant effect for the 6 post-traumatic 
UWS patients but produced some improvement for 5 of the 19 
post-traumatic MCS patients. No adverse tDCS-related side 
effects were observed.
Discussion
rTMS in the Treatment of TBi
The reviewed reports reveal that rTMS can be effective in reducing 
neurological and psychiatric symptoms that arise as a result of a 
TBI. Improvements were documented in single-case reports for 
patients presenting with hemispatial neglect, tinnitus, auditory 
hallucinations, depression, and executive dysfunction. A  larger-
group study found that the majority of patients showed reduced 
post-concussion symptoms following rTMS intervention, though 
a sham control group was not provided. In the studies that com-
pleted follow-up examinations, some improvements were shown to 
persist, in varying degrees, in the weeks or months post-treatment. 
In this regard, rTMS demonstrates a similar ability to produce 
sustained symptom relief in post-TBI sequelae as in comparable 
non-trauma induced symptoms. Results were less encouraging 
with regards to the use of rTMS in states of altered consciousness. 
One study reported rTMS-induced neurobehavioral changes and 
improved consciousness, but additional attempts to recreate these 
results were unsuccessful. Results were also inconclusive with 
regards to the ability of rTMS to reduce suicidal ideation.
The inherent variability in the location and extent of brain 
injuries means that the symptoms and treatment requirements in 
each case will be different. Indeed, the reviewed reports showed 
a great variety in the severity and location of injuries, as well as 
the protocols and stimulation parameters used in their treatment. 
The versatility of rTMS makes it an excellent match for such a 
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varied disorder, as the therapeutic use of the technique can be 
adapted to each individual case. However, this same variability 
makes it difficult to broadly determine its efficacy as a treatment. 
It is likely that there will never be a single and ideal protocol for 
the use of rTMS in TBI. Instead, its use will be most effective 
if tailored to the specific requirements of each patient or to a 
common set of symptoms.
The main concern with regards to the use of rTMS in cases of 
TBI is safety. TBI has generally been considered a contraindication 
for rTMS due to its association with an increased overall neural 
excitability and subsequent seizure risk. Indeed, patients with 
severe TBI do show an increased risk of unprovoked seizures, as 
shown by a standardized incidence ratio (SIR) of 17.0 compared 
to the normal population (65, 66). For this reason, care should be 
taken when considering rTMS treatment for this patient group. 
Nielson et al. suggest that brain scans and neurosurgical reports 
should be consulted prior to treatment of severe TBI in order 
to evaluate the location and severity of cortical lesions or skull 
plates that could unpredictably alter the path of TMS currents 
through brain tissue (67). In addition, they recommend the use 
of neuronavigational software to avoid direct stimulation of these 
potential hazards, as well as computational modeling of currents 
if stimulation is being applied close to a lesion or plate (67).
There is a strong connection between the severity of a brain 
injury and the subsequent risk of seizures; individuals with mild 
to moderate TBI have a substantially lower seizure risk than those 
with severe TBI. Several studies have found that any increase in 
the risk of seizures following a mild TBI is either marginal or non-
existent compared to the general population (68, 69). It should be 
noted that Ferguson et al. did find a significant increase in seizure 
occurrence for individuals who were hospitalized with mild TBI 
(70). However, the authors point out that since 87.5% of people 
who attend an emergency room with a mild TBI are not hospital-
ized, their results may be skewed toward more ‘severe’ cases of 
mild TBI (70, 71). These findings suggest that rTMS treatment 
may not pose a significantly greater health risk in cases of mild 
TBI than in the general population. Nonetheless, the fact that 
mild TBI could present even a marginal increase in seizure risk is 
enough to warrant extra precautions.
The reviewed studies reveal that a number of methods are 
already being employed to help reduce the chance of an adverse 
event. Chiefly, EEG recordings have been used to monitor brain 
activity for any evidence of epileptiform discharge prior to, during, 
and/or following treatment. This technique is invaluable insofar as 
its ability to provide clinicians with real-time brain activity read-
ings during rTMS administration. Despite this obvious utility, 
EEG recordings at baseline or even during treatment may not be 
sufficient to predict a seizure. For example, in the seizure incident 
reported by Cavinato and colleagues (50), the patient experienced 
a seizure 3 h post-treatment. In this case, clinicians had taken an 
EEG measurement at baseline but not during treatment sessions. 
However, the delay between the treatment session and the onset 
of the seizure suggests that brain activity indicating an impending 
seizure may not be immediately obvious. Nonetheless, the ability 
to monitor brain activity for epileptiform discharge throughout 
treatment is valuable. Additionally, imaging techniques, such 
as MRI and PET, enable clinicians to screen for lesions or other 
trauma-induced abnormalities that may unpredictably affect 
rTMS currents and pose a risk to the patient’s safety.
Nielson and colleagues recently released a list of preliminary 
guidelines for the safe administration of rTMS to individuals with 
moderate to severe TBI (67). These guidelines suggest the use of 
low-frequency rTMS, along with the exclusion of individuals 
with a history of seizures, ferrous metallic implants, or medica-
tions that are known to reduce seizure threshold. The authors 
also recommend that physicians review patients’ neuroimaging 
and neuropsychiatric reports prior to treatment to ensure that 
rTMS can safely be administered to the target area. Similarly, Reti 
and colleagues have suggested the following exclusion criteria for 
TBI patients who are being considered for rTMS treatment for 
depression: severe TBI; a history of seizures; lesions, contusions, 
hematomas, or surgery in the area to be treated; and the pres-
ence of a brain tumor, skull fracture, or non-TBI cerebral lesion 
(72). The authors also recommend that rTMS treatment not be 
performed within the first 3 months following a TBI due to the 
heightened risk of spontaneous seizure in this period and the fact 
that neuropsychiatric symptoms may still resolve spontaneously.
Both Nielson and Reti suggest that the use of low-frequency 
rTMS may be preferable to high-frequency stimulation for cases 
of TBI (67, 72). As previously discussed, low-frequency (≤1 Hz) 
stimulation is thought to reduce cortical excitability (23, 24), as 
observed through reductions in ipsilateral motor evoked poten-
tials (73) and decreases in regional cerebral blood flow (74, 75). 
Furthermore, low-frequency rTMS has been shown to reduce 
seizure incidence in epileptic patients (76). Importantly, there is 
evidence that low-frequency rTMS to the right DLPFC can be 
as effective as high-frequency rTMS to the left DLPFC in the 
treatment of major depression (77). Taken together, these factors 
suggest that low-frequency rTMS may well be a superior choice 
for the treatment of depression in TBI patients given the higher 
likelihood of increased cortical excitability in this population. 
However, limiting TBI patients to low-frequency stimulation 
protocols may be unduly restrictive, especially given the low 
seizure risk in individuals with mild TBI and the fact that high-
frequency stimulation may be the preferred treatment option for 
select TBI-related symptoms. For example, in a recent review of 
rTMS as a potential treatment for co-occurring alcohol abuse 
disorder, TBI, and post-traumatic stress disorder, Herrold and 
colleagues suggest that high-frequency, supra-threshold rTMS 
stimulation of the right DLPFC could help promote recovery 
(78). Nielson and colleagues accept that protocols exceeding 
their preliminary guidelines may be justifiable given appropri-
ate compensatory steps to avoid seizure and sufficient expected 
benefits to warrant the risk. Careful consideration will have to be 
taken when comparing the risk of high-frequency stimulation in 
cases of moderate or severe TBI with the potential benefit to the 
patient of successful treatment.
The reviewed reports demonstrate that rTMS can be effective in 
treating symptoms of TBI, particularly in cases that do not involve 
disorders of consciousness. However, most of the current evidence 
is based on single-case reports and studies that lack sham stimula-
tion or control groups. Larger-group, blinded, randomized, and 
controlled studies are necessary before firm conclusions can be 
drawn. The dramatic difference in seizure risk as well as type and 
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severity of symptoms across the continuum of mild to severe TBI 
cases requires that additional investigations be undertaken to dif-
ferentiate the efficacy of rTMS depending on injury severity. The 
amount of time elapsed since injury may also play a role in the 
effectiveness and tolerability of rTMS treatment. The initial find-
ing of well tolerated intervention, especially amongst mild TBI 
patients, prompts a possible re-examination of the general safety 
guidelines for rTMS which currently include TBI as an exclusion 
criterion. The preliminary guidelines for the safe use of rTMS for 
TBI by Nielson et al. provide a basis for this revision.
tDCS in the Treatment of TBi
The reviewed studies show that the use of tDCS in cases of TBI 
has primarily been targeted at improving cognitive impairments 
and altered states of consciousness. tDCS has demonstrated 
some potential in its ability to alter attention in patients, as 
shown by a temporary improvement in MMSE score and reac-
tion time following a single stimulation session (59). Kang et al. 
proposed that repeated sessions of longer duration or higher 
intensity could produce longer-lasting effects. However, two later 
studies found no significant benefit to a wide range of cognitive 
abilities  –  including attention, memory, and cognitive flexibil-
ity –  following repeated applications of tDCS compared to sham 
(60, 63). Given that Lésniak et al. specifically recruited patients 
who had suffered a severe TBI, it is possible that the severity of 
injuries alters the efficacy of tDCS intervention. As may be the 
case with rTMS, the efficacy of tDCS may vary depending on both 
severity and time since injury.
Transcranial Direct Current Stimulation has thus far demon-
strated a limited ability to improve altered states of conscious-
ness. Roughly a quarter of TBI patients exhibiting a minimally 
conscious state showed a minor response to tDCS, whereas only 
one of nine patients with UWS showed a definite benefit from 
intervention (58, 62). Thibaut and colleagues suggest that the 
patient’s initial level of consciousness prior to intervention may 
be indicative of the efficacy of tDCS in such cases, with higher 
initial consciousness ratings faring better (62). With limited 
data on which to draw conclusions, further investigation will be 
required to ascertain the true efficacy of tDCS for TBI symptoms.
One major benefit of tDCS with this patient population is its 
relative safety, as tDCS does not confer the same seizure risk as 
rTMS (44, 59). Indeed, no major adverse effects were reported 
in any of the reviewed studies. In addition to the improvement 
of chronic symptoms post-TBI, it has been suggested that tDCS 
may also be beneficial in preventing brain damage during acute 
stages of injury by reducing glutamatergic hyperexcitability (79). 
Based on their observation that greater pre-treatment slowing 
in EEG is associated with more extensive neuropsychological 
improvements following tDCS, Ulam et  al. suggest that EEG 
recording could be used as a potential biological marker of a posi-
tive response to tDCS treatment in the acute phase of TBI (63). 
This assertion is reinforced by their reported correlation between 
change in cortical excitability and neuropsychological improve-
ment in the active tDCS group. Non-invasive brain stimulation 
may prove to be an important tool for increasing the efficacy of 
other recovery techniques by modulating neural plasticity after 
an acquired brain injury (80).
Conclusion
Preliminary examinations of studies suggest that non-invasive 
brain stimulation techniques show potential in the treatment 
of TBI-related symptoms. While there is not yet enough data to 
draw conclusions as to the definite efficacy of rTMS or tDCS in 
TBI, the reviewed studies provide preliminary evidence that these 
methods can produce positive results in certain cases and that 
treatment is generally well tolerated. Larger blinded, randomized, 
controlled trials matched for age/sex, time since injury, and sever-
ity of symptoms must be conducted before firm conclusions can 
be drawn regarding their efficacy and safety. In the case of rTMS, 
patients would benefit from further improvement of guidelines to 
ensure safe protocols are followed in order to minimize the risk of 
adverse effects, such as seizure and syncope.
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